Introduction
Activation of the T-cell antigen receptor (TCR) results in the recruitment and activation of members of both the Src and Syk families of cytoplasmic tyrosine kinases (reviewed in Latour and Veillette, 2001 ). The subsequent phosphorylation of downstream targets by these kinases triggers a signalling cascade that ultimately results in the transcriptional upregulation of genes such as IL-2, a growth-promoting cytokine. Adaptor proteins such as SLP-76, Gads, and LAT form a complex that plays a critical role in the assembly of multimolecular signalling complexes downstream of the activated TCR, permitting propagation of the T-cell signal to the nucleus (Zhang et al., 1998; Clements et al., 1999; Liu et al., 1999; Rudd, 1999) .
A number of membrane bound and cytosolic adaptor proteins, such as PAG, members of the Dok family, and c-Cbl downregulate TCR signalling, and are essential for the maintenance of T-cell homeostasis. c-Cbl, a ubiquitously expressed protein, initially characterized as an adaptor protein, functions as a negative regulator of both receptor and nonreceptor tyrosine kinases. It possesses a RING finger domain and has E3 ubiquitin ligase activity that promotes ubiquitination of activated tyrosine kinases (Joazeiro et al., 1999) . Following TCR activation, c-Cbl is known to be recruited to the activated TCR complex and tyrosine phosphorylated. Recruitment of c-Cbl to the activated TCR leads to its association with the Syk family kinases, SYK and ZAP-70. The association between c-Cbl and the Syk family kinases has been demonstrated to result in a decrease in their activity and protein levels (Lupher et al., 1998; Murphy et al., 1998; Rao et al., 2000) , resulting in an overall downregulation of signalling from the TCR. The mechanism by which c-Cbl negatively regulates SYK and ZAP-70 is not fully understood, however, it has been proposed that c-Cbl ubiquitin ligase activity may be involved in this process. Recently, SYK has been shown to be a direct target for c-Cbl ubiquitination in Bcells (Rao et al., 2001) , and through an adaptor function of ZAP-70, c-Cbl has been demonstrated to ubiquitinate the TCR zeta chain, a critical component of the TCR : CD3 complex (Wang et al., 2001 ). c-Cbl-mediated ubiquitination of components of the TCR could result in either degradation via the proteasome or, alternatively, could serve as a signal for trafficking of the activated TCR complex to the lysosome. Mice deficient in c-Cbl have been observed to possess both increased cell surface TCR on thymocytes and elevated levels of tyrosine phosphorylated ZAP-70 (Murphy et al., 1998; Thien et al., 1999) .
Another adaptor protein that negatively regulates signalling from the activated TCR is the Src-like adaptor protein (SLAP) (Sosinowski et al., 2000) . Interestingly, targeted disruption of the SLAP gene in mice also results in increased surface TCR expression in thymocytes , implying that similar to c-Cbl, SLAP might affect trafficking of the TCR. The precise mechanism by which SLAP mediates its effect on the TCR remains to be elucidated.
Recently, the cloning and characterization of a novel adaptor protein, Src-like adaptor protein 2 (SLAP-2), bearing significant sequence and structural similarity to SLAP, has been described (Holland et al., 2001; Loreto et al., 2002; Pandey et al., 2002) . The murine SLAP-2 protein consists of an amino-terminal myristoylation sequence that is responsible for targeting SLAP-2 to cellular membranes, a Src homology 3 (SH3) domain and a Src homology 2 (SH2) domain, as well as a unique carboxy-terminal region. The expression of SLAP-2 protein appears to be restricted to hematopoietic tissues and cell lines. In T cells, SLAP-2 associates both in vitro and in vivo with the E3 ubiquitin ligase c-Cbl, an interaction that has been mapped to the SLAP-2 carboxy-terminus. Functionally, the overexpression of SLAP-2 in T cells leads to an inhibition of TCR- Schematic representation of the genomic structure of the coding region of the human SLAP-2 gene. GenBank accession numbers for the corresponding genomic DNA clones are indicated above the schematic. Numbering above the boxes refers to coding exons (I-VII), and the numbers within the boxes denote the number of amino acids encoded by each of the exons. The number of base pairs for each of the respective introns is also indicated. (c) Intron-exon table highlighting the sequence context of the splice junctions of the human SLAP-2 gene. The numbering refers to the coding exons. The corresponding amino acid sequences are indicated by letters above the nucleotide sequences, which start and complete each of the exons mediated NFAT activation, suggesting that SLAP-2 is a negative regulator of TCR signal transduction (Holland et al., 2001; Loreto et al., 2002; Pandey et al., 2002) . Importantly, the inhibition of TCR-mediated NFAT activation by SLAP-2 is dependent on its interaction with c-Cbl (Loreto et al., 2002) . Overexpression of SLAP-2 in Jurkat cells leads to decreased ZAP-70 protein levels and diminished levels of CD3 on the cell surface, suggesting that SLAP-2 regulates TCR signalling by facilitating the c-Cbl-mediated downregulation of the activated TCR complex, perhaps through ubiquitination (Loreto et al., 2002) .
Here we report the cloning of a cDNA encoding the human homologue of SLAP-2, as well as the genomic structure of the human SLAP-2 gene. Similar to its murine counterpart, human SLAP-2 protein expression is hematopoietic-specific, with expression observed in a variety of hematopoietic cell lines, of both the lymphoid and myeloid lineages. The coding region of the human SLAP-2 gene consists of seven exons, and the gene is located on chromosome 20q, a region that is commonly deleted in myeloproliferative disorders. As well, we report the identification of SLAP-2-v, an alternatively spliced SLAP-2 isoform that lacks the c-Cbl interaction region, and consequently is impaired in its capacity to both bind to c-Cbl, and inhibit TCR signalling relative to SLAP-2.
Results
Cloning of the human SLAP-2 cDNA and determination of the genomic structure and chromosomal localization of the human SLAP-2 gene Employing the National Center for Biotechnology (NCBI) BLAST algorithm, the murine SLAP-2 cDNA sequence was used to search human high-throughput genomic DNA sequences (htgs) on the Genbank sequence database. Several overlapping genomic clones contained regions of the SLAP-2 coding sequence. The full-length coding region of the human SLAP-2 cDNA was subsequently cloned from human thymus cDNA with gene-specific PCR primers. The 783 bp cDNA encodes a putative protein of 261 amino acids, two amino acids longer than its murine counterpart ( Figure 1a) . Using both the mouse and human cDNA sequences as a guide, the genomic structure of the coding region of the human SLAP-2 gene was deduced, and the exon/intron boundaries were established from the various human genomic clones (Figure 1b and c) . The coding region of the human SLAP-2 gene consists of seven exons, with all exon/intron splice sites conforming to the eukaryotic GT/AG splice rule (Mount, 1982) . Exons 2 and 3 encode the SH3 domain, while exons 4 and 5 encode the SH2 domain. The intra-SH2 intron located between exons 4 and 5 is very large (B17 kb), and the seven exons span approximately 28 kb of genomic sequence. This genomic structure is nearly identical to that which was recently described for murine and human SLAP (Kratchmarova et al., 2001) , suggesting a common ancestry of these two genes. One of the genomic clones that was used to determine the structure of the SLAP-2 gene was annotated as mapping to chromosome 20q 11.21-23. Confirmation of the chromosomal localization of SLAP-2 to 20q was obtained by fluorescence in situ hybridization (FISH; data not shown).
Expression of SLAP-2 in human cell lines
In order to profile human SLAP-2 protein expression, immunoblots were performed on protein extracts from a number of human hematopoietic and nonhematopoietic cell lines using an antibody generated against the carboxy-terminus of murine SLAP-2 (Figure 2a ). Consistent with the expression profile of the murine protein, the expression of human SLAP-2 was restricted to hematopoietic cells. SLAP-2 protein was detected in the B-cell lines Raji and Ramos, the Jurkat T-cell line, and the natural killer cell line, YT. Additionally, SLAP-2 protein expression was observed in myeloid cell lines, including KG la, and OCI-AML-2,3, and 5, indicating Expression profiling of the human SLAP-2 protein with the murine SLAP-2 antibody failed to detect the two alternative translation isoforms that had previously been observed for the murine protein, raising the possibility that only one isoform is expressed in human cells. This seemed unlikely, however, as the predicted site of alternative translation initiation is conserved in the human homologue. Using an antibody generated against the human SLAP-2 carboxy-terminus (ahSLAP-2-C) to immunoprecipitate SLAP-2 from Jurkat cells revealed that two human SLAP-2 translation isoforms are expressed (Figure 2b) . Therefore, similar to its murine counterpart, alternative translation initiation results in the expression of protein isoforms of approximately 28 and 25 kDa, respectively.
Identification of an alternatively spliced SLAP-2 isoform
In addition to the expected full-length human SLAP-2 cDNA, PCR-based cloning from human thymus cDNA also yielded a shorter SLAP-2 cDNA. Based on the deduced genomic structure of the human SLAP-2 gene, it was apparent that the shorter cDNA represented a SLAP-2 isoform derived from alternative splicing. We have designated this alternative form of SLAP-2 as SLAP-2-v. In the variant, exon 5 (which completes the SH2 domain) is spliced to exon 6 at an internal splice acceptor site (Figure 3a and b) . This alternative splicing removes 50 bp of exon 6, and results in the introduction of an alternative reading frame, and translation termination early in exon 7. This unique cDNA has an open-reading frame that encodes a putative protein of 210 amino acids, with a unique carboxy-terminal amino acid sequence (Figure 3c ). Analysis of the murine SLAP-2 sequence revealed conservation of the alternative splice acceptor site, and the predicted protein product of (Figure 3d) .
Expression of the SLAP-2-v transcript has been confirmed by RT-PCR from a number of RNA sources (data not shown). In order to detect the expression of the SLAP-2-v protein, a polyclonal antibody that specifically recognizes the unique carboxyterminal region of SLAP-2-v was generated (aSLAP-2-v). This antibody detects a protein of the predicted size in peripheral blood lymphocytes that comigrates with the upper band of the SLAP-2-v proteins expressed in transfected cells, confirming endogenous expression of the SLAP-2-v protein in human lymphocytes (Figure 3e) . Transfection of the SLAP-2-v cDNA in COS cells resulted in the expression of two immunoreactive proteins. These likely arise from alternative translation initiation as the SLAP-2-v mRNA contains both initiation methionines found in the hSLAP-2 cDNA. Among the cell lines surveyed for SLAP-2-v protein, expression was observed in the Jurkat T-cell line and the KGla myeloid cell line (Figure 3f ).
SLAP-2-v is impaired in its ability to associate with c-Cbl and inhibit TCR-mediated NFAT activation
We have previously shown that the inhibitory effect of SLAP-2 on signalling downstream of the activated TCR is dependent on the SLAP-2 carboxy-terminal region, which mediates the interaction with c-Cbl (Loreto et al., 2002) . In order to assess the ability of SLAP-2-v to interact with c-Cbl, GST-SLAP-2, and GST-SLAP-2-v were used to test in vitro association with endogenous c-Cbl in Jurkat cell lysates (Figure 4a ). SLAP-2-v retains the ability to associate with tyrosine phosphoproteins of 70 and 72 kDa (we have previously identified the 70 kDa protein as ZAP-70), but is compromised in its ability to associate with c-Cbl. Furthermore, we found that GSTCbl-N fusion protein bound to SLAP-2, but not to SLAP-2-v, when these proteins were expressed in Jurkat cells (Figure 4b) . Consistent with the inability of SLAP-2-v to associate with c-Cbl, it had reduced (but not completely ablated) capacity to inhibit TCRmediated NFAT activation, relative to SLAP-2 ( Figure 5 ). 
Discussion
We have cloned the cDNAs encoding human SLAP-2 and an alternatively spliced SLAP-2 isoform, which has been designated SLAP-2-v. Human SLAP-2 protein is expressed in hematopoietic cell lines, in cells of both lymphoid and myeloid lineage. Among lymphoid lineage cells, SLAP-2 expression was observed in T-, natural killer, and B-cell lines. The expression of SLAP-2 protein in KGla cells is a novel observation extending the expression of SLAP-2 to myeloid lineage cells. This is of particular interest given the chromosomal localization of the human SLAP-2 gene to chromosome 20q, a region of the genome that is frequently deleted in myeloproliferative disorders. Loss of 20q11 is proposed to contribute to the etiology of this group of premalignant hyperproliferative disorders of the myeloid cell population (Roulston et al., 1993) . In our survey of human cell lines, SLAP-2 protein expression was not observed in either the K562 or U937 myeloid leukemia cell lines. Interestingly, both of these cell lines have been described cytogenetically as having deletions of chromosome 20q (MacGrogan et al., 2001) . Given the negative regulatory role that SLAP-2 has been demonstrated to play in T cells through its association with the E3 ubiquitin ligase c-Cbl, and the observed expression of SLAP-2 protein in myeloid lineage cells, SLAP-2 represents a candidate 20q tumor suppressor gene.
Alternative translation initiation of both mouse and human SLAP-2 results in the expression of protein isoforms of approximately 28 and 25 kDa, respectively, with the smaller isoform lacking both the myristoylation sequence and serine-rich region present at the amino terminus of the long isoform. In most murine cell lines, p28 SLAP-2 is more abundant than p25 SLAP-2, except in the thymus, where we observed higher levels of p25 (Loreto et al., 2002) . While the consequences of fluctuations in the relative levels of expression of p28 and p25 SLAP-2 remain to be more fully investigated, the p25 isoform could serve to target c-Cbl to a different subcellular location or antagonize the function of p28. The p28 and p25 murine isoforms have been shown to be differentially localized to the membrane and cytoplasm, respectively, and mutation of the amino-terminal myristoylation site of p28 was shown to reduce its capacity to negatively regulate TCR-mediated NFAT activation (Holland et al., 2001; Loreto et al., 2002; Pandey et al., 2002) .
In addition to the alternative translation isoforms, we have identified SLAP-2-v, which is derived from alternative splicing. Expression of the SLAP-2-v protein in hematopoietic cell lines appears to differ somewhat from that of SLAP-2. Similar to SLAP-2, SLAP-2-v was detected in Jurkat T cells and the KGla myeloid cell line; however, unlike SLAP-2, SLAP-2-v, was not found to be expressed in either of the YT or Ramos cell lines. Two SLAP-2-v protein species of approximately 23 and 20 kDa, respectively, are expressed in Jurkat and KGla cells, presumably because of alternative translation initiation. A combination of alternative translation initiation and alternative splicing of SLAP-2, therefore, results in the expression of four distinct protein isoforms of approximately 28, 25, 23, and 20 kDa, respectively. While we have not directly identified the 23 and 20 kDa forms in murine cells, sequence analysis suggests that all four forms of mSLAP-2 exist as well.
While the alternative translation initiation affecting the amino-terminal region of the protein appears likely to influence the localization of SLAP-2 and associated proteins, the carboxy-terminus of SLAP-2 is required for association with c-Cbl and negative regulation of TCR-mediated NFAT activation (Loreto et al., 2002) . Therefore, as expected, the unique carboxy-terminal region present in SLAP-2-v greatly diminishes its capacity to associate with c-Cbl, and consequently, to inhibit TCR-mediated NFAT activation. The observation that SLAP-2-v retains a reduced (but not completely ablated) capacity to inhibit NFAT activation may be because of its ability to maintain a reduced association with c-Cbl, either directly through a region outside of its carboxy-terminus, or indirectly, via its association with ZAP-70. Alternatively, it is possible that the unique SLAP-2-v carboxy-terminus associates with distinct signalling molecules that are yet to be identified.
In summary, we have described the cloning and genomic characterization of human SLAP-2 and identified a human SLAP-2 splice variant, SLAP-2-v. The expression of SLAP-2 in myeloid lineage cells as well as its localization to chromosome 20q may be of significance in myeloproliferative disorders in which 20q is deleted. As well, the existence of an alternative splice variant that is compromised in its ability to interact with c-Cbl and has a reduced capacity to inhibit TCRmediated NFAT activation further highlights the potentially complex role of SLAP-2 in the regulation of hematopoietic cell signalling.
Materials and methods
Cloning of human SLAP-2 and SLAP-2-v cDNAs, and genomic structure determination of the human SLAP-2 gene Using the murine SLAP-2 cDNA, a search of high-throughput genomic sequences in the GenBank sequence database was conducted to identify regions of the human genome encoding the human SLAP-2 homologue. Three overlapping genomic sequences containing regions of the human SLAP-2 gene were identified (GenBank accession numbers: AL031662, AC026539, and AL050318). Based on the sequence contained in these clones, gene-specific primers were designed to PCR amplify the full-length human SLAP-2 cDNA (PCR primers: 5 0 -atgggaagtctgcccagcagaag-3 0 (sense) and 5 0 -ctaggcatcatccaaagagacagcc-3 0 (anti-sense)). Using this approach, cDNAs of 783 and 734 bp, respectively, were amplified and cloned from human thymus pooled cDNA (Clontech). These sequence data have been submitted to GenBank and are available under the accession numbers AF290985 (SLAP-2) and AF290986 (SLAP-2-v). Exon-intron boundaries for the human SLAP-2 gene were deduced from the cDNA sequences of mouse and human SLAP-2.
Cell lines and primary cells
COS-1, Hela and 293 T cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% (vol/vol) fetal bovine serum (Gibco BRL), 200 mm l-glutamine, 5 U/ml penicillin C, and 5 mg/ml streptomycin sulfate. Raji, Ramos, BJAB, Jurkat, YT, K562, and U937 cells were cultured in RPMI 1640 medium supplemented as above. KGla cells were cultured in Iscove's media supplemented with 20% (vol/vol) fetal bovine serum, 200 mm l-glutamine, 5 U/ml penicillin C, and 5 mg/ml streptomycin sulfate. Human peripheral blood lymphocytes (PBLs) were isolated from whole blood using Lympholyte reagent (Cedarlane), according to the manufacturer's protocol.
Antibodies
Polyclonal anti-mouse SLAP-2 antisera (amSLAP-2-C) were produced in rabbits as described previously (Loreto et al., 2002) . Affinity-purified amSLAP-2-C was used for immunoblotting at a dilution of 1 : 1000. Polyclonal anti-human SLAP-2 antisera (ahSLAP-2-C) were produced by immunizing rabbits with a peptide containing the carboxy-terminal 13 amino acids of the human SLAP-2 protein (NH 3 -ISLN-DEAVSLDDA-COOH). Five microliters of crude ahSLAP-2-C or preimmune serum was used for immunoprecipitation, and crude ahSLAP-2-C was used at a dilution of 1 : 500 for immunoblotting. Polyclonal anti-human SLAP-2-v antisera (aSLAP-2-v) were produced by immunizing rabbits with a GST fusion protein containing the unique carboxy-terminal region of the human SLAP-2-v protein. Five microliters of crude aSLAP-2-v or preimmune serum was used for immunoprecipitation, and crude aSLAP-2-v was used at a dilution of 1 : 500 for immunoblotting. Antiphosphotyrosine MAb 4G10 was purchased from Upstate Biotechnology Inc., and used at a dilution of 1 : 1000 for immunoblotting. Rabbit anti-c-Cbl (C-15) polyclonal antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and used at a dilution of 1 : 500 for immunoblotting. Anti-MYC MAb 9E10 was purchased from the Developmental Studies Hybridoma Bank (University of Iowa) and used at a dilution of 1 : 1000 for immunoblotting. Sheep anti-mouse antibody (1 : 6000 dilution) and protein A (1 : 3000 dilution) conjugated to horseradish peroxidase (HRP) were used to detect bound primary mouse MAbs and polyclonal antibodies, respectively.
Immunoprecipitation and Western blotting
Cells were lysed in 1 ml of PLC lysis buffer (50 mm HEPES pH 7.5, 150 mm NaCl, 10% (vol/vol) glycerol, 1% (vol/vol) Triton X-100, 1.5 mm MgCl, 1 mm EDTA, 10 mm NaPPi, 100 mm NaF) containing complete protease inhibitors (Roche). Cell lysates were cleared by centrifugation at 14 000 r.p.m. (20 800 g) and 41C for 10 min. Lysates were incubated with antibodies and 50 ml of 20% (vol/vol) protein G-Sepharose (Sigma; for immunoprecipitation with MAbs) or protein ASepharose beads (for immunoprecipitation with polyclonal antibodies) at 41C with gentle rotation for 90 min. Immune complexes were washed four times in 1 ml of cold 1% NP-40 lysis buffer, and bound proteins were eluted by boiling for 5 min in 2 Â SDS sample buffer. Eluted proteins were resolved by SDS-PAGE on 10-15% gels. Proteins were electrophoretically transferred to polyvinylidene difluoride membranes (NEN Life Science) and incubated in a blocking solution of 5% (wt/vol) skim milk powder in 1 Â Tris-buffered saline with 0.05% Tween 20 (TEST) or 1% (wt/vol) bovine serum albumin in I Â TBST (antiphosphotyrosine blotting) for a minimum of 30 min prior to the additon of primary antibodies. Blocked membranes were incubated with primary antibodies as described, at room temperature for 1 h. Membranes were washed three times for 10 min with IX TBST at room temperature and incubated for 45 min with the appropriate secondary antibody conjugated to HRP. Bound antibodies were detected using enhanced chemiluminescence reagent (NEN Life Science).
Mammalian expression constructs and GST fusion proteins
Full-length SLAP-2 and SLAP-2-v cDNAs were cloned in frame into the pEF-MYC/His (EcoRI/XbaI) mammalian expression vector, and into pGEX-4Tl (EcoRI/XhoI) in order to express GST fusion proteins in bacteria. The SLAP-2-v cDNA was also cloned into the pIRES-EGFP2 (EcoRI/ BamHI) mammalian expression vector. The Cbl-N GST fusion construct was a gift from Hamid Band and has been described previously (Lupher et al., 1997) .
Cell stimulation
Jurkat E6.1 cells were stimulated with anti-CD3e antibody (monoclonal antibody (MAb) clone UCHT1; 2 mg) for 2 min at 371C. Following stimulation, Jurkat T-cells were lysed in Nonidet P40 (NP-40) lysis buffer (50 mm HEPES (pH 7.5), 150 mm NaCl, 10% (vol/vol) glycerol, 1% (vol/vol) NP-40, 0.1 mm ZnCl 2 , 2mm EDTA) containing complete protease inhibitors (Roche) and 1 mm sodium orthovanadate.
In vitro binding assays
GST fusion proteins were produced in bacteria and purified on glutathione-Sepharose beads (Pharmacia). In vitro binding assays were done with Jurkat T-cell lysates (20 Â l0 6 cells) either unstimulated or stimulated with anti-CD3 antibody (Pharmingen). Lysates were incubated with B4 mg of GST fusion proteins for 90 min at 41C. Following several washes, bound proteins were eluted in 2X sodium dodecyl sulfate (SDS) sample buffer and resolved by SDS-PAGE. Membranes were subsequently stained with Coomassie blue dye to ensure equal loading of fusion proteins. ) were electroporated (250 V, 960 mF) with 40 mg of either empty pEF vector, SLAP-2 or SLAP-2-v expression vectors and 10 mg of NFATluciferase reporter construct. NFAT-luciferase assays were conducted as previously described Berry et al., 2001) .
